Local control and toxicity after stereotactic radiotherapy in brain metastases patients and the impact of novel systemic treatments
Name:
PIIS0167814024035187.pdf
Size:
2.216Mb
Format:
PDF
Description:
Found with Open Access Button
Authors
van Schie, P.Huisman, R. G.
Wiersma, T.
Knegjens, J. L.
Navran, A.
Brandsma, D.
Compter, A.
Bot, M.
Hoogmoed, J.
de Witt Hamer, P. C.
Post, R.
Borst, Gerben R
Affiliation
Division of Cancer Sciences, School of Medical Sciences; School of Biological Sciences, Faculty of Biology, Medicine and Health & Manchester Cancer Research Centre, Manchester Academic Health Science Centre (MAHSC), University of Manchester, United Kingdom; Departments of Clinical Oncology; The Christie NHS Foundation Trust, Manchester, United Kingdom.Issue Date
2024
Metadata
Show full item recordAbstract
BACKGROUND AND PURPOSE: Treatment modalities for patients with brain metastases consist of surgery, radiotherapy, and systemic treatments such as immunotherapy and targeted therapy. Although much is known about local control of brain metastases after radiotherapy and surgery alone, more understanding is needed of the additional effect of new systemic treatments. Our study presents real-world data about the combined effects of different local and systemic treatment strategies on local response of irradiated brain metastases. MATERIALS AND METHODS: We performed a retrospective consecutive cohort study of patients that presented with brain metastases in our institution between June 2018 and May 2020, reporting the impact of radiotherapy alone versus radiotherapy combined with systemic treatment on local control of irradiated brain metastases and toxicity. Chemotherapy and targeted therapy were temporarily discontinued around irradiation. RESULTS: 262 consecutively treated patients were included in the study. Median time to local failure of irradiated brain metastases was 18 months (IQR 9-34), median overall survival was 20 months (IQR 10-36). 211 (81 %) patients received systemic treatment. Patients with breast cancer had a worse local control (HR 2.3, 95 % CI 1.0-5.0, p = 0.038), as did patients without any systemic treatment (HR 2.1, 95 % CI 1.1-4.3, p = 0.034). Symptomatic radiation necrosis occurred in 36 (14 %) patients. A diameter > 2.5 cm was associated with a higher risk of radiation necrosis. No association was found between systemic treatment in combination with local radiotherapy and symptomatic radiation necrosis. CONCLUSION: Patients who received any form of systemic treatment had better local control after stereotactic radiosurgery for brain metastases. We did not find an association between systemic treatment and the incidence of radiation necrosis.Citation
van Schie P, Huisman RG, Wiersma T, Knegjens JL, Navran A, Brandsma D, et al. Local control and toxicity after stereotactic radiotherapy in brain metastases patients and the impact of novel systemic treatments. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2024 Nov;200:110540. PubMed PMID: 39293720. Epub 2024/09/19. eng.Journal
Radiotherapy and OncologyDOI
10.1016/j.radonc.2024.110540PubMed ID
39293720Additional Links
https://dx.doi.org/10.1016/j.radonc.2024.110540Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2024.110540
Scopus Count
Collections
Related articles
- Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
- Authors: Angelov L, Mohammadi AM, Bennett EE, Abbassy M, Elson P, Chao ST, Montgomery JS, Habboub G, Vogelbaum MA, Suh JH, Murphy ES, Ahluwalia MS, Nagel SJ, Barnett GH
- Issue date: 2018 Aug
- Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery.
- Authors: McKay WH, McTyre ER, Okoukoni C, Alphonse-Sullivan NK, Ruiz J, Munley MT, Qasem S, Lo HW, Xing F, Laxton AW, Tatter SB, Watabe K, Chan MD
- Issue date: 2017 Jul
- Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
- Authors: Parsai S, Miller JA, Juloori A, Chao ST, Kotecha R, Mohammadi AM, Ahluwalia MS, Murphy ES, Barnett GH, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH
- Issue date: 2020 Feb 1
- Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
- Authors: Frakes JM, Figura NB, Ahmed KA, Juan TH, Patel N, Latifi K, Sarangkasiri S, Strom TJ, Chinnaiyan P, Rao NG, Etame AB
- Issue date: 2015 Nov
- Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects.
- Authors: Diao K, Bian SX, Routman DM, Yu C, Kim PE, Wagle NA, Wong MK, Zada G, Chang EL
- Issue date: 2018 Dec 1